Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway

被引:80
|
作者
de Angelis, L
Zhao, JH
Andreucci, JJ
Olson, EN
Cossu, G
McDermott, JC
机构
[1] York Univ, Dept Biol, N York, ON M3J 1P3, Canada
[2] Univ Roma La Sapienza, Ist Istol & Embriol Gen, I-00161 Rome, Italy
[3] Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
[4] DIBITH San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy
关键词
p38; MAPK; MEF2; muscle regulatory factors;
D O I
10.1016/j.ydbio.2005.04.009
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Biochemical and cell culture studies have characterized the myocyte enhancer factor 2 (MEF2) transcriptional regulatory proteins as obligatory partners for the myogenic regulatory factors (MRFs) in the differentiation of myogenic cells in culture. However, the role of MEF2 activation in somitic myogenesis has not been fully characterized. Here, we report a critical interaction between the p38 mitogen-activated protein kinase (p38 MAPK) and MEF2 in the developing somite myotome. We document expression of MEF2A and p38 MAPK proteins in the somite of 9.5 dpc mouse embryos concurrent with Myf 5 protein expression. We also observed that abrogation of p38 MAPK signaling blocks MEF2 activation using a MEF2 transgenic 'sensor' mouse. Inhibition of p38 MAPK signaling concurrently inhibited myogenic differentiation in somite cultures and in embryos in vivo using transplacental injection of a p38 inhibitor (SB203580). Finally, we document that commitment to the myogenic lineage is not appreciably affected by p38 MAPK inhibition since the activation of an early marker of myogenic commitment (Myf 5) occurs normally when p38 MAPK signaling is inhibited. Thus, we present novel evidence indicating a crucial role for p38 MAPK signaling to the MEF2 transcriptional regulators during early mammalian somite development and myotome formation. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 50 条
  • [41] AKT-independent activation of p38 MAP kinase promotes vascular calcification
    Yang, Youfeng
    Sun, Yong
    Chen, Jianye
    Bradley, Wayne E.
    Dell'Italia, Louis J.
    Wu, Hui
    Chen, Yabing
    REDOX BIOLOGY, 2018, 16 : 97 - 103
  • [42] Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase
    Laufer, Stefan
    Lehmann, Frank
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (05) : 1461 - 1464
  • [43] Induction of ROS, p38 MAP Kinase and Apoptosis via Pulmonary Toxic Drugs
    Song, Mee
    Kim, Youn-Jung
    Ryu, Jae-Chun
    BIOCHIP JOURNAL, 2009, 3 (04) : 306 - 315
  • [44] INDUCTION OF HEMOLYSIS AND ERYPTOSIS BY OCCUPATIONAL POLLUTANT NICKEL CHLORIDE IS MEDIATED THROUGH CALCIUM INFLUX AND P38 MAP KINASE SIGNALING
    Alfhili, Mohammad A.
    Alamri, Hassan S.
    Alsughayyir, Jawaher
    Basudan, Ahmed M.
    INTERNATIONAL JOURNAL OF OCCUPATIONAL MEDICINE AND ENVIRONMENTAL HEALTH, 2022, 35 (01)
  • [45] p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation
    Stanton, LA
    Sabari, S
    Sampaio, AV
    Underhill, TM
    Beier, F
    BIOCHEMICAL JOURNAL, 2004, 378 : 53 - 62
  • [46] MAP kinase p38 is a novel target of CacyBP/SIP phosphatase
    Agnieszka M. Topolska-Woś
    Sara Rosińska
    Anna Filipek
    Amino Acids, 2017, 49 : 1069 - 1076
  • [47] Synthesis development of a naphthyridinone p38 kinase inhibitor
    Chung, John Y. L.
    Cvetovich, Raymond J.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2006, 9 (06) : 792 - 805
  • [48] An updated patent review of p38 MAP kinase inhibitors (2014-2019)
    Haller, Vanessa
    Nahidino, Philipp
    Forster, Michael
    Laufer, Stefan A.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (06) : 453 - 466
  • [49] Anisomycin superinduces annexin V mRNA expression through the ERK1/2 but not the p38 MAP kinase pathway
    Konishi, Y
    Sato, H
    Tanaka, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 313 (04) : 977 - 983
  • [50] Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy
    Zhang, Jian
    Yan, Chen
    He, Weidong
    Wang, Min
    Liu, Jian
    PANMINERVA MEDICA, 2020, : 365 - 371